Lindis Blood Care raises €1.4M Series B round
12 December 2024· Hennigsdorf, Germany· health, biotech, b2b, deep_hardware, medical_devices
The new investment will be used to prepare for the anticipated approval of the medical device (CE Mark) and product launch of CATUVAB in Europe, as well as progressing the FDA marketing approval process in the US.
Investors
LeadBrandenburg Kapital
Also participating
High-Tech GründerfondsSeedBlinkFranzpeter BrachtHorst Lindhofer
About Lindis Blood Care
Stage
Series B
Headquarters
Hennigsdorf, Germany
Founded
2018
Team Size
21–50
Sectors
healthbiotechb2bdeep_hardwaremedical_devices